Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) announced today that it will participate in the DealFlow Discovery Conference, scheduled for January 28–29, 2026, in Atlantic City, New Jersey. The company's Chief Executive Officer, Geordan Pursglove, will conduct one-on-one meetings with investors during the conference, providing an opportunity to discuss Lixte's clinical development programs.
The conference participation underscores Lixte's ongoing efforts to advance LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), through clinical development. According to the press release, LB-100 has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Preclinical data published on the company's website (www.lixte.com) suggest that LB-100 has the potential to enhance the efficacy of chemotherapies and immunotherapies, potentially improving outcomes for cancer patients.
Lixte is a clinical-stage pharmaceutical company focused on developing cancer therapies targeting new biological pathways. Its lead compound, LB-100, is part of a novel approach called "activation lethality," which represents a new treatment paradigm in cancer biology. The company holds a comprehensive patent portfolio covering this approach. Currently, proof-of-concept clinical trials are underway for ovarian clear cell carcinoma and metastatic colon cancer.
Investors interested in Lixte can find the latest news and updates in the company's newsroom at http://ibn.fm/LIXT. The DealFlow Discovery Conference, which brings together biotechnology companies and investors, provides a platform for Lixte to share its progress and engage with potential partners.
The announcement of Lixte's participation in the conference is significant for stakeholders as it highlights the company's commitment to advancing its clinical pipeline and seeking strategic alliances. With LB-100 targeting a novel mechanism in cancer treatment, the outcomes of ongoing trials could have substantial implications for patients with difficult-to-treat cancers.
